Sign up USA
Proactive Investors - Run By Investors For Investors

Allergan to buy body contouring company Zeltiq Aesthetics

Pharmaceutical group Allergan has announced the acquisition of Zeltiq Aesthetics for $2.475bn to gain access to its body contouring technology.
Allergan to buy body contouring company Zeltiq Aesthetics
Allergan is to buy Zeltiq Aesthetics

Botox maker Allergan (NYSE:AGN) has agreed to buy body contouring company Zeltiq Aesthetics for $2.475bn.

Dublin-based Allergan will pay $56.50 per Zeltiq share, a 14.4% premium to the group’s closing price on Friday.

The acquisition will give Allergan access to Zeliq’s body contouring technology, CoolSculpting System, which reduces stubborn fat cells that may not respond to diet or exercise.

The technology will compliment Allergan’s treatment, Kybella, which is used to reduce fat under the chin.

Allergan said body contouring presents a $4bn market opportunity worldwide and the purchase of Zeltiq will be immediately earnings accretive.

 "With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices," chairman and chief executive Brent Saunders said.

The acquisition is subject to shareholder approval.

Since its $160bn merger with Pfizer collapsed in April, Allergan has been involved in a batch of deals including the acquisition of Acelity's LifeCell.

Allergan announced it was buying LifeCell, which produces products for breast reconstruction and soft tissue repair, in December and it is expected to boost the company’s earnings in coming years. 



Register here to be notified of future AGN Company articles
View full AGN profile

Allergan Timeline

Newswire
February 08 2017
Newswire
December 20 2016
Newswire
November 02 2016
Article
September 20 2016
Newswire
August 15 2016
Newswire
August 08 2016

Related Articles

Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
Cynata-CEO-Dr-Ross-Macdonald-presenting-Syd-Mar-2017.jpg
March 16 2017
Dr Ross Macdonald talked stemcell research with investors.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use